Clinical Trial

Renal Denervation in Chronic Kidney Disease - RDN-CKD Study

Study acronym: RDN-CKD GR
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
RDN-CKD GR Study is a prospective, randomized (1:1), double-blind (unblinded interventionalist and blinded study team), sham controlled study. The purpose of the RDN-CKD GR Study is to demonstrate that renal denervation (RDN) effectively reduces 24-h ambulatory BP in 20 patients with chronic kidney disease (CKD) stage 3a or 3b.
Trial Details
NCT Number NCT07742787
Lead Sponsor Hippocration General Hospital
Collaborators: ReCor Medical, Inc.
Conditions Uncontrolled Hypertension, Renal Denervation, Chronic Kidney Disease (Stage 3)
Enrollment 20 participants
Start Date 2024-07-04
Primary Completion 2026-09-06 (estimated)
Study Completion 2027-03-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-04